Axial spondyloarthritis - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Axial spondyloarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Axial spondyloarthritis: Overview
The term axial spondyloarthritis covers both the early inflammatory phase of the disease in which there is no structural damage in the sacroiliac joints (non-radiographic disease) and the later stages in which structural damage is visible on X?ray scans of the sacroiliac joints as erosions, sclerosis or bony bridges (radiographic disease; also known as ankylosing spondylitis). In addition, patients with radiographic axial spondyloarthritis might have abnormalities in X?ray scans of the spine, the most important one being syndesmophytes (vertical bony growth between the corners of two vertebral bodies).
Axial spondyloarthritis is divided into non-radiographic and radiographic disease (also known as ankylosing spondylitis) according to the presence of radiographic changes of the sacroiliac joints. Changes in the spine evident on X-ray can occur in radiographic axial spondyloarthritis, but spinal radiographs can also be normal.
'Axial spondyloarthritis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Axial spondyloarthritis pipeline landscape is provided which includes the disease overview and Axial spondyloarthritis treatment guidelines. The assessment part of the report embraces, in depth Axial spondyloarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Axial spondyloarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Axial spondyloarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Axial spondyloarthritis Emerging Drugs
Further product details are provided in the repor
Axial spondyloarthritis: Therapeutic Assessment
This segment of the report provides insights about the different Axial spondyloarthritis drugs segregated based on following parameters that define the scope of the report, such as:
Axial spondyloarthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Axial spondyloarthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Axial spondyloarthritis drugs.
Axial spondyloarthritis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Axial spondyloarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Axial spondyloarthritis: Overview
The term axial spondyloarthritis covers both the early inflammatory phase of the disease in which there is no structural damage in the sacroiliac joints (non-radiographic disease) and the later stages in which structural damage is visible on X?ray scans of the sacroiliac joints as erosions, sclerosis or bony bridges (radiographic disease; also known as ankylosing spondylitis). In addition, patients with radiographic axial spondyloarthritis might have abnormalities in X?ray scans of the spine, the most important one being syndesmophytes (vertical bony growth between the corners of two vertebral bodies).
Axial spondyloarthritis is divided into non-radiographic and radiographic disease (also known as ankylosing spondylitis) according to the presence of radiographic changes of the sacroiliac joints. Changes in the spine evident on X-ray can occur in radiographic axial spondyloarthritis, but spinal radiographs can also be normal.
'Axial spondyloarthritis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Axial spondyloarthritis pipeline landscape is provided which includes the disease overview and Axial spondyloarthritis treatment guidelines. The assessment part of the report embraces, in depth Axial spondyloarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Axial spondyloarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Axial spondyloarthritis R&D. The therapies under development are focused on novel approaches to treat/improve Axial spondyloarthritis.
This segment of the Axial spondyloarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Axial spondyloarthritis Emerging Drugs
- Tofacitinib: Pfizer
- Bimekizumab: UCB Biopharma
- Tildrakizumab: Sun Pharma Global
Further product details are provided in the repor
Axial spondyloarthritis: Therapeutic Assessment
This segment of the report provides insights about the different Axial spondyloarthritis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Axial spondyloarthritis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Oligonucleotide
- Recombinant fusion proteins
- Small molecule
- Peptide vaccine
- Product Type
Axial spondyloarthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Axial spondyloarthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Axial spondyloarthritis drugs.
Axial spondyloarthritis Report Insights
- Axial spondyloarthritis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Axial spondyloarthritis drugs?
- How many Axial spondyloarthritis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Axial spondyloarthritis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Axial spondyloarthritis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Axial spondyloarthritis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Pfizer
- Mycenax Biotech
- Clover Biopharmaceuticals
- Celltrion
- UCB
- Gilead Sciences
- Amgen
- Genrix (Shanghai) Biopharmaceuticals
- Sun Pharma Global
- Boehringer Ingelheim
- Jiangsu HengRui Medicine
- Izana Bioscience
- 3SBio
- Tasly Pharmaceuticals Inc.
- Suzhou Zelgen Biopharmaceuticals
- Affibody
- Kinevant Sciences
- Qyuns Therapeutics
- Akeso Biopharma
- Jiangsu HengRui Medicine Co., Ltd
- FunPep Co Ltd.
- Luye Pharma Group
- siRNAgen Therapeutics
- Aclaris Therapeutics
- Dice molecules
- Tofacitinib
- ENIA11
- SCB-808
- CT-P17
- Bimekizumab
- Filgotinib
- Apremilast
- GR1501
- Tildrakizumab
- BI 730357
- SHR0302
- Namilumab
- SSS07
- Jitongning tablets
- Jaktinib
- ABY-035
- KIN-1901
- QX002N
- AK111
- SHR-1314
- FPP003
- TS8108
- Amphisiran
Introduction
Executive Summary
Axial spondyloarthritis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Axial spondyloarthritis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Axial spondyloarthritis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Axial spondyloarthritis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Bimekizumab: UCB Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Namilumab: Izana Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
KIN-1901: Kinevant Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Axial spondyloarthritis Key Companies
Axial spondyloarthritis Key Products
Axial spondyloarthritis- Unmet Needs
Axial spondyloarthritis- Market Drivers and Barriers
Axial spondyloarthritis- Future Perspectives and Conclusion
Axial spondyloarthritis Analyst Views
Axial spondyloarthritis Key Companies
Appendix
Executive Summary
Axial spondyloarthritis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Axial spondyloarthritis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Axial spondyloarthritis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Axial spondyloarthritis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Bimekizumab: UCB Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Namilumab: Izana Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
KIN-1901: Kinevant Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Axial spondyloarthritis Key Companies
Axial spondyloarthritis Key Products
Axial spondyloarthritis- Unmet Needs
Axial spondyloarthritis- Market Drivers and Barriers
Axial spondyloarthritis- Future Perspectives and Conclusion
Axial spondyloarthritis Analyst Views
Axial spondyloarthritis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Axial spondyloarthritis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Axial spondyloarthritis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Axial spondyloarthritis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Axial spondyloarthritis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
